CD8A and graft versus host disease: IL-15/IL-15Ra-Fc (ALT-803) therapy (NCT01885897), for instance, promoted an increase in CD8+ T-cells of the effector or effector memory phenotype without increasing Tregs, and no patient developed severe GVHD despite the induction of CD8+ T-cell activation [51].